Long Term, Registry-Based, Prospective, Post-Authorization Safety Study Evaluating Adverse Events of Special Interest in Patients with Highly Active Relapsing Multiple Sclerosis Newly Started on Cladribine Tablets − CLARION

Helmut Butzkueven, P Korhonen, Jan Hillert, M Trojano, A Aydemir, Melinda Magyari, H Khanfir, C Pinuaga, Meritxell Sabidó